Michael Mortensen
Chief Operating Officer at BONESUPPORT HOLDING AB
Net worth: 828 085 $ as of 2024-03-30
Profile
Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate from the University of Copenhagen, and an MBA from AVT Business School A.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BONESUPPORT HOLDING AB
0.06% | 2024-03-04 | 38,835 ( 0.06% ) | 828 085 $ | 2024-03-30 |
Michael Mortensen active positions
| Companies | Position | Start |
|---|---|---|
| BONESUPPORT HOLDING AB | Chief Operating Officer | 2021-11-30 |
Nanovi Radiotherapy A/S
 Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Corporate Officer/Principal | - |
Training of Michael Mortensen
| Technical University of Denmark | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
| AVT Business School A/S | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BONESUPPORT HOLDING AB | Health Technology |
| Private companies | 1 |
|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
- Stock Market
- Insiders
- Michael Mortensen
